JOHN E. KAO - 10 Sep 2025 Form 4 Insider Report for Alignment Healthcare, Inc. (ALHC)

Role
Chief Executive Officer, Director
Signature
/s/ Christopher J. Joyce, as Attorney-in-Fact, for John E. Kao
Issuer symbol
ALHC
Transactions as of
10 Sep 2025
Net transactions value
-$8,779,961
Form type
4
Filing time
10 Sep 2025, 20:04:02 UTC
Previous filing
13 Aug 2025
Next filing
14 Oct 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
KAO JOHN E Chief Executive Officer, Director 1100 W. TOWN & COUNTRY RD., SUITE 1600, ORANGE /s/ Christopher J. Joyce, as Attorney-in-Fact, for John E. Kao 10 Sep 2025 0001222028

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALHC Common Stock Sale $4,120,749 -253,908 -5.2% $16.23 4,634,678 10 Sep 2025 Direct F1, F2
transaction ALHC Common Stock Sale $1,704,260 -101,110 -2.2% $16.86 4,533,568 10 Sep 2025 Direct F1, F3
transaction ALHC Common Stock Sale $2,954,952 -180,000 -13% $16.42 1,193,100 10 Sep 2025 See Footnote F4, F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This transaction does not represent a discretionary trade by the reporting person.
F2 The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $15.74 to $16.735. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.
F3 The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $16.74 to $17.24. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.
F4 Date of Rule 10b5-1 plan adoption: 03/12/2025
F5 The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $16.03 to $16.73. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.
F6 Represents securities held by JEK Trust, dated February 8, 2021, of which Mr. Kao is the trustee.